Targeting tumor-associated macrophages in cancer therapy and understanding their complexity

由 Cannarile, Michael A., Ries, Carola H., Hoves, Sabine, Rüttinger, Dominik
發表在 Oncoimmunology (2014)

Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

由 Cannarile, Michael A., Weisser, Martin, Jacob, Wolfgang, Jegg, Anna-Maria, Ries, Carola H., Rüttinger, Dominik
發表在 J Immunother Cancer (2017)

Transcriptional regulator Id2 controls survival of hepatic NKT cells

由 Monticelli, Laurel A., Yang, Yang, Knell, Jamie, D'Cruz, Louise M., Cannarile, Michael A., Engel, Isaac, Kronenberg, Mitchell, Goldrath, Ananda W.
出版 2009

Systematic evaluation of immune regulation and modulation

由 Stroncek, David F., Butterfield, Lisa H., Cannarile, Michael A., Dhodapkar, Madhav V., Greten, Tim F., Grivel, Jean Charles, Kaufman, David R., Kong, Heidi H., Korangy, Firouzeh, Lee, Peter P., Marincola, Francesco, Rutella, Sergio, Siebert, Janet C., Trinchieri, Giorgio, Seliger, Barbara
發表在 J Immunother Cancer (2017)

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity

由 Hoves, Sabine, Ooi, Chia-Huey, Wolter, Carsten, Sade, Hadassah, Bissinger, Stefan, Schmittnaegel, Martina, Ast, Oliver, Giusti, Anna M., Wartha, Katharina, Runza, Valeria, Xu, Wei, Kienast, Yvonne, Cannarile, Michael A., Levitsky, Hyam, Romagnoli, Solange, De Palma, Michele, Rüttinger, Dominik, Ries, Carola H.
發表在 J Exp Med (2018)

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I—conceptual challenges

由 Rutella, Sergio, Cannarile, Michael A, Gnjatic, Sacha, Gomes, Bruno, Guinney, Justin, Karanikas, Vaios, Karkada, Mohan, Kirkwood, John M, Kotlan, Beatrix, Masucci, Giuseppe V, Meeusen, Els, Monette, Anne, Naing, Aung, Thorsson, Vésteinn, Tschernia, Nicholas, Wang, Ena, Wells, Daniel K, Wyant, Timothy L, Cesano, Alessandra
發表在 J Immunother Cancer (2020)

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II—practical challenges

由 Cesano, Alessandra, Cannarile, Michael A, Gnjatic, Sacha, Gomes, Bruno, Guinney, Justin, Karanikas, Vaios, Karkada, Mohan, Kirkwood, John M, Kotlan, Beatrix, Masucci, Giuseppe V, Meeusen, Els, Monette, Anne, Naing, Aung, Thorsson, Vésteinn, Tschernia, Nicholas, Wang, Ena, Wells, Daniel K, Wyant, Timothy L, Rutella, Sergio
發表在 J Immunother Cancer (2020)

First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors

由 Menke-van der Houven van Oordt, C. Willemien, Gomez-Roca, Carlos, van Herpen, Carla, Coveler, Andrew L., Mahalingam, Devalingam, Verheul, Henk M. W., van der Graaf, Winette T. A., Christen, Randolph, Rüttinger, Dominik, Weigand, Stefan, Cannarile, Michael A., Heil, Florian, Brewster, Michael, Walz, Antje-Christine, Nayak, Tapan K., Guarin, Ernesto, Meresse, Valerie, Le Tourneau, Christophe
發表在 Oncotarget (2016)

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

由 Machiels, Jean-Pascal, Gomez-Roca, Carlos, Michot, Jean-Marie, Zamarin, Dmitriy, Mitchell, Tara, Catala, Gaetan, Eberst, Lauriane, Jacob, Wolfgang, Jegg, Anna-Maria, Cannarile, Michael A, Watson, Carl, Babitzki, Galina, Korski, Konstanty, Klaman, Irina, Teixeira, Priscila, Hoves, Sabine, Ries, Carola, Meneses-Lorente, Georgina, Michielin, Francesca, Christen, Randolph, Rüttinger, Dominik, Weisser, Martin, Delord, Jean-Pierre, Cassier, Philippe
發表在 J Immunother Cancer (2020)